<DOC>
	<DOCNO>NCT02285920</DOCNO>
	<brief_summary>The SPin-D Trial phase II randomize , double-blind , placebo-controlled , multi-center study spironolactone ( SPL ) patient hemodialysis-dependent end-stage renal disease .</brief_summary>
	<brief_title>Safety Cardiovascular Efficacy Spironolactone Dialysis-Dependent ESRD Trial</brief_title>
	<detailed_description>The primary objective study characterize safety tolerability multiple dose chronic SPL therapy compare placebo maintenance hemodialysis patient assess feasibility conduct full-scale , mortality-powered trial SPL . The effect SPL compare placebo multiple cardiovascular efficacy parameter also analyze . The primary efficacy parameter change E ' measurement tissue Doppler echocardiography ( TDI ) index diastolic function surrogate myocardial fibrosis . Secondary cardiac parameter interest study overall population sub-studies include heart rate variability , circulate marker fibrosis , coronary flow reserve ( CFR ) index microvascular function . These parameter design broaden insight potential effect SPL cardiac structure function individual dialysis-dependent ESRD ass feasibility conduct full-scale , mortality-powered trial .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . Maintenance hemodialysis therapy endstage renal disease 2 . Age 1885 year 3 . ≥3 calendar month since dialysis initiation . Note patient dialysis ≥3 le 6 calendar month , must hospitalizations 6 week prior screen , change estimate dry weight ( EDW ) within 2 week screen date . 4 . For woman childbearing potential , willingness use highly effective method birth control 4 week last dose study drug . 5 . Ability provide inform consent 1 . Serum potassium ≥6.5 mEq/L within 3 month prior screen 2 . Serum potassium level ≥6.0 mEq/L within 2 week prior baseline visit . If potassium value available routine clinical care 2week period potassium measurement perform research test . 3 . Unscheduled dialysis hyperkalemia within 3 month prior screen 4 . Predialysis systolic blood pressure &lt; 100 mm Hg within 2 week prior screen baseline visit 5 . 2 dialysis session within month prior screen either 2 intradialytic measurement systolic blood pressure &lt; 80 mm Hg muscle cramping , lightheadedness , nausea hypotension require infusion saline intervention direct hypotension 6 . Current dual use angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) 7 . Current use digoxin 8 . Current use spironolactone eplerenone 9 . Allergy spironolactone 10 . Inability maintain dialysis machine blood flow ≥300 mL/min recent 3 dialysis session prior screen visit indicator vascular access dysfunction 11 . Mitral valve repair replacement 12 . Severe mitral valve disease echocardiography , coronary angiography cardiac magnetic resonance image 13 . Anticipated kidney transplant , change peritoneal dialysis , transfer another dialysis unit within 9 month 14 . Expected survival &lt; 9 month 15 . Pregnancy , anticipated pregnancy , breastfeed 16 . Incarceration 17 . Participation another intervention study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>spironolactone</keyword>
	<keyword>cardiac fibrosis</keyword>
	<keyword>diastolic function</keyword>
</DOC>